Acadia Healthcare (NASDAQ:ACHC) Updates FY 2024 Earnings Guidance

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.400-3.700 for the period, compared to the consensus earnings per share estimate of 3.540. The company issued revenue guidance of $3.2 billion-$3.3 billion, compared to the consensus revenue estimate of $3.2 billion. Acadia Healthcare also updated its FY24 guidance to $3.40-3.70 EPS.

Analyst Ratings Changes

Several research firms have recently commented on ACHC. Mizuho upped their price objective on Acadia Healthcare from $77.00 to $84.00 and gave the stock a neutral rating in a research note on Wednesday, March 6th. Barclays started coverage on shares of Acadia Healthcare in a report on Wednesday, March 6th. They issued an overweight rating and a $100.00 target price for the company. TheStreet raised shares of Acadia Healthcare from a c rating to a b- rating in a report on Monday, March 4th. UBS Group upped their target price on shares of Acadia Healthcare from $88.00 to $102.00 and gave the stock a buy rating in a report on Wednesday, February 28th. Finally, Cantor Fitzgerald reaffirmed a neutral rating and issued a $90.00 target price on shares of Acadia Healthcare in a report on Tuesday, March 5th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $92.00.

Acadia Healthcare Price Performance

Shares of ACHC traded down $0.95 during midday trading on Wednesday, hitting $72.99. 706,913 shares of the company traded hands, compared to its average volume of 571,092. The firm has a 50 day moving average of $77.71 and a 200-day moving average of $77.72. Acadia Healthcare has a 52 week low of $66.49 and a 52 week high of $87.77. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of -291.95, a PEG ratio of 2.20 and a beta of 1.31. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.67 and a current ratio of 0.67.

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.80 by $0.05. Acadia Healthcare had a negative net margin of 0.74% and a positive return on equity of 11.21%. The business had revenue of $742.80 million during the quarter, compared to the consensus estimate of $727.60 million. During the same quarter in the prior year, the firm earned $0.70 EPS. The business's revenue was up 10.0% on a year-over-year basis. On average, analysts forecast that Acadia Healthcare will post 3.57 EPS for the current fiscal year.

Insider Activity at Acadia Healthcare

In related news, Director Wade D. Miquelon sold 2,203 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $85.39, for a total value of $188,114.17. Following the completion of the transaction, the director now owns 46,074 shares of the company's stock, valued at approximately $3,934,258.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is owned by insiders.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.